Presentation and Status in Health Basket
Presentation | Basket | Yarpa | Pharmasoft |
---|---|---|---|
Inhaler 200 doses |
|
59982 | 1906 |
Related information
Dosage
The dosage should be adapted to the individual requirements of the patient; patients should also be kept under medical supervision during treatment. It is advisable not to greatly exceed the recommended daily dose during both acute and maintenance treatment. If therapy does not produce a significant improvement or if the patient’s condition worsens, medical advice must be sought in order to determine a new regimen of therapy. In the case of acute or rapidly worsening dyspnea, a doctor should be consulted immediately. The recommended dosage is as follows:
Adults: Usually 1 or 2 puffs four times daily, although some patients may need up to 4 puffs at a time to obtain maximum benefit during early treatment. However, the total number of inhalations should not exceed 12 in 24 hours.
Children: 6-12 years: Usually 1 or 2 puffs three times daily. In order to ensure that the inhaler is used correctly, administration should be supervised by an adult.
The dose recommendations are the same for children < 6 years of age. As there is insufficient ex-perience in this age group, inhalation of the product should be medically supervised
Indications
For the relief of symptoms of reversible bronchospasm associated with asthma, chronic bronchitis and emphysema.
Contra-Indications
Hypersensitivity to the drug, to atropine and its derivatives. Hypersensitivity to any other ingredient of the preparation.
Special Precautions
Hypersensitivity
Immediate hypersensitivity reactions may occur following the use of Ipratropium bromide, as demonstrated, for example, by rare cases of rash, urticaria, angioedema, oropharyngeal oedema, bronchospasm and anaphylaxis.
Paradoxical bronchospasm
As with other inhaled medications, Ipratropium bromide may cause paradoxical bronchospasm, which may be life-threatening. If paradoxical bronchospasm occurs, Atrovent must be discontinued immediately and replaced with an alternative therapy.
Special populations
Ocular complications
Atrovent should be used with caution in patients with a predisposition for narrow-angle glaucoma.
If the product accidentally comes into contact with the eyes during use, mild, reversible ocular complications may occur. There is a risk of an acute glaucoma attack, particularly in patients with narrow-angle glaucoma; the characteristic symptoms are eye pain, blurred vision, visual halos or coloured images, red eyes and corneal oedema.
If mydriasis and mild accommodation disturbances occur, treatment with miotic drops may be given. In the event of severe ocular complications, an ophthalmologist should also be consulted.
As the inhaler is used in conjunction with a mouthpiece and is operated manually, the risk of the mist getting into the eyes is low.
Effect on the kidneys and urinary tract
In patients with micturition disorders (such as in prostatic hypertrophy or bladder neck obstruction), the benefit of treatment with ipratropium bromide must be carefully weighed against the potential risk of aggravating urinary retention.
Gastrointestinal motility disorders
Patients with cystic fibrosis are more likely to develop gastrointestinal motility disorders.
Contains alcohol (less than 100 mg per dose).
See prescribing information for full details.
Side Effects
Headache, dizziness, taste disturbance, Cough, irritation in the throat, Dry mouth, disturbed gastrointestinal motility, nausea. See prescribing information for full details.
Pregnancy and Lactation
Pregnancy: The safety of ipratropium during human pregnancy has not been established. The benefits of using ipratropium bromide during a confirmed or suspected pregnancy must be weighed against possible hazards to the unborn child.
Lactation: It is not known whether ipratropium is secreted into breast milk. Although lipid-insoluble quaternary cations pass into breast milk, it is unlikely that ipratropium bromide would reach the infant to an important extent, when administered by inhalation. However, because many drugs are secreted into breast milk, caution should be exercised when ipratropium bromide is administered to nursing mothers.
See prescribing information for full details.
Overdose
No symptoms specific to overdose have been encountered to date. In view of the wide therapeutic range and topical route of administration of ipratropium bromide inhalation, however, no serious anticholinergic symptoms are to be expected. Mild systemic anticholinergic effects such as dry mouth, ocular accommodation disturbances and increase in heart rate are possible.
Important notes
Pharmaceutical Precautions: Store below 30°C and protect from heat and direct sunlight. The vials should not be punctured or incinerated even when apparently empty.
Warning: Pressure container. Do not puncture, break, or incinerate even when empty.